The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study.
 
Akihiro Ohba
Honoraria - Ono Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Ono Pharmaceutical
 
Yuki Takumoto
No Relationships to Disclose
 
Takeshi Terashima
Speakers' Bureau - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Novartis; Taiho Oncology
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Kobayashi
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kenji Ikezawa
Speakers' Bureau - MSD; Ono Pharmaceutical; Taiho Oncology; Yakult Honsha
Research Funding - ASKA Pharmaceutical
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - GlaxoSmithKline
 
Nao Fujimori
No Relationships to Disclose
 
Hidetaka Tsumura
No Relationships to Disclose
 
Go Murohisa
No Relationships to Disclose
 
Ayano Ohya
No Relationships to Disclose
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly; Sumitomo Dainippon Pharma Oncology; Takeda
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst)
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroto Narimatsu
Research Funding - Chugai Pharma; Takeda
 
Manabu Akazawa
Honoraria - Takeda
Consulting or Advisory Role - Shionogi
 
Takeru Shiroiwa
No Relationships to Disclose
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)